7/12/2023 0 Comments Nova development corporation![]() ![]() Rascan added, “NOVA has laid the necessary groundwork to quickly move in 2022 to submit applications to the regulatory agencies in the U.S., Canada, and Europe for phase 2A clinical studies of psilocybin in fragile X syndrome (FXS), a rare disease with unmet medical needs. We, despite being a small drug biotech company, have achieved tremendous progress last year in our psilocybin research and drug development program, as well as established new partnerships that will help accelerate our efforts and guide us on the pathway to drug approval and commercialization.” ![]() NOVA updates on 2021 milestonesĬEO & President of NOVA, Will Rascan, said, “As we enter 2022, I want to thank NOVA’s shareholders for their continued support and investment in our company. Nova Mentis Life Science Corp (OTCMKTS: NMLSF) has reviewed its 2021 pharmaceutical development milestones and highlighted its planned 2022 initiatives toward drug approvals and commercialization.
0 Comments
Leave a Reply. |